Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Biosimilar Index: Tracking the Biosimilar Development Landscape

Product Code:
596200232
Latest Update:
March 2016
Format:
Excel & Powerpoint
Pages:
Bi-monthly datafile update and 200+ slide monthly report

FirstWord’s Biosimilar Index is a comprehensive drug intelligence service that provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets in development worldwide. Exhaustively referenced and sourced, it is one of the most comprehensive analyses of its type providing both on-going tracking of development and interpretation of the commercial and clinical significance.

Request a demo today.

Biosimilar Index now includes details of 593 biosimilar and NCB programmes and is segmented by developing company, reference molecule, market status and therapeutic class, making it one of the most detailed biosimilar market tracking tools available today. Biosimilar Index provides a collection of key journal articles, news stories, key regulatory developments, licensing availability and partnering information for all key programmes.  All information is sorted in an easy-to-search tab of the datafile with links to source information.

Biosimilar R&D activity is at an all-time high and, at this critical stage in the market’s evolution, it is vital to fully understand the biosimilar and non-comparable biologic (NCB) pipeline and be able to draw reliable conclusions about what is, and is not, significant. That is where the Biosimilar Index comes in.

Now Available
Podcast: Interview with Dr Paul Calvo, IP and Legal Expert
Webinar [On-Demand]: What’s Next for Biosimilars? History, Current Status and Future Expectations

Two Comprehensive Services in One Subscription

Biosimilar Index: Pipeline Datafile

Updated ​every two weeks, this Datafile provides up-to-date insight of biosimilar and NCB drugs in development from over​ 189​ ​ companies worldwide. The Datafile can be downloaded (as often as you need) in MS Excel™ format.

The latest version of the Biosimilar Index datafile includes details of​ 59​3 biosimilar and NCB programmes. It continues to be segmented by developing company (​n=189 companies), reference molecule (​n=54 molecules), market status (n=17 markets) and therapeutic class (n=1​6​ classes), making it one of the most detailed biosimilar market tracking tools available today. The datafile also includes (1) a list of approved biosimilars from several of the key developed and emerging markets; (2) a summary of all key product updates since the service began back in March 2014; (3) a collection of key biosimilar-focused journal articles, news stories and key regulatory developments and; (4) licensing availability and partnering information for all key programmes.

Biosimilar Index Landscape Review

Published monthly and delivered in MS PowerPoint™, the Landscape Review is packed with slides of tables and charts on key reference medicinal product data, current and future market milestones, extensive product-by product reviews and relevant clinical trial activity. The Landscape Review is based on the updated research in the Biosimilar Index: Pipeline Datafile and enhanced by critical insights from in house and external biosimilar experts.

The latest version includes market landscape summaries and detailed reviews of all key clinical trials across a wide number of molecules, including all key monoclonal antibodies (mAbs), fusion proteins, insulin, EPO-alfa, filgrastim, follicle stimulating hormone, interferon-alfa and interferon-beta. Also includes a review of the latest news and events in the biosimilars market and FirstView's proprietary Biosimilars Market Catalyst Calendar which aims to provide visibility of several key future milestones in the biosimilars market.

 

Key Benefits and Features

With Biosimilar Index you can...

  • Understand the biosimilar and NCB development landscape through comprehensive coverage of the pipelines of all major biosimilar developers worldwide
  • Drill down to discover the levels of potential biosimilar competition by therapy area, drug class status and geography
  • Establish the level of biosimilar competition for leading biologic brands
  • Learn which biosimilar developers are potential future competitors or collaborators
  • Identify the biosimilar and NCB portfolios of over 160 companies and discover the leaders in product development for which products/therapy areas
  • Know where the development hotspots are and what research is taking place.

The Biosimilar Index is feature rich...

  • Includes both structured data and commercial interpretation
  • The Biosimilar Index: Pipeline Datafile covers all significant biosimilar products and is updated daily. Available 24/7 in MS Excel™ with unlimited downloads which can be incorporated into your own analytics package or visualisation software
  • The Biosimilar Index: Landscape Review provides and insightful quarterly analysis which identifies the developments that are really important
  • Biosimilar Index is Informed by a wide-range of respected sources with expert internal and external inputs and oversight

For multi-user pricing, please contact us at info@firstviewreports.com

Biosimilar Index: Pipeline Datafile

The Biosimilars Index: Pipeline Datafile is checked regularly. When a significant event happens, the datafile is updated, thereby ensuring you’re up to date with current market dynamics. The datafile is provided as a dynamic MS Excel™ file with complete data and filter analysis tools included. Available 24/7 through a secure password protected site, there are no limits on how frequently you can download the XLS file. Having access to the datafile enables you to see the whole biosimilar and NCB landscape across multiple classes and geographies

Essential details covered in the datafile include:

  • Brand name(s) of reference
  • Indications and reported sales for the reference product
  • Originator company
  • Biosimilars development company
  • HQ location of development company
  • Therapy class
  • Key indication(s)
  • Mode of application and route of administration
  • Clinical trials status
  • Global marketing status
  • Marketing agreements and licensing opportunities

Powerful data with intuitive analysis tools

With Biosimilars Index: Pipeline Datafile at hand, you can effortlessly compare and contrast biosimilars in development by country, originator company, stage of development, condition and therapeutic area. The data is provided in MS Excel™ and comes with filters and search built in. The data can easily be exported to your own analytics package or data visualisation platform.

Biosimilar Index: Landscape Review

What’s hot and what’s not? The biosimilars sector is constantly evolving. Important research progress, commercial deals and product launches are regularly announced. The Biosimilar Index: Landscape Review strips away market rumour and speculation to tell you exactly what has happened and why it is important. Published monthly, the Landscape Review is based on the daily-updated research in the Biosimilar Index: Pipeline Datafile, enhanced by critical insights and understanding from biosimilars experts.

Benefits and Features of the Biosimilar Index: Landscape Review

  • Includes essential structured data including
    • Sales data for reference products
    • Current and future market milestones
    • Individual single view analysis for leading products
    • Clinical trial activities and flow charts of development phase.
  • The service draws on a wide-range of reliable information sources such as clinical trial registries, company communications, conference proceedings, broker analysis and social media.
  • Includes powerful interpretation and analysis by knowledgeable experts to ensure that developments are scrutinised and the implications highlighted.
  • Presented in MS PowerPoint™ to bring clarity to the extensive charting and tables provided which can be incorporated into your own presentations.

Request a demo today.

Expert Input

Duncan Emerton, Senior Director Syndicated Insights and Analytics

FirstWord’s Biosimilar Index is headed up by Dr Duncan Emerton, a recognised expert in the biosimilar field.

With over 15 years clinical research and commercial analysis experience gained with Pfizer and Datamonitor, Duncan brings a unique and informed perspective to the expanding market for biosimilars and the commercial, clinical and regulatory challenges it faces.

Duncan is a regular presenter and Chair at biosimilar-focused conferences and has contributed several acclaimed articles and book chapters on key issues including lifecycle management, profitability, commercialisation and strategy.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors, and your markets.  Topics cover Market Access, Medical Affairs, Pharmaceutical Sales and Marketing, Technology, Biosimilars and Therapy Areas.



customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved